Alesi Surgical Ltd has raised $8.7 million in new investment capital from investors. The funding round will support the company's mission to develop and commercialise products that improve the safety, efficacy, and outcomes of surgical procedures. Alesi Surgical is known for its Ultravision2 smoke management solution, which attained FDA clearance in 2023. This system includes the world’s first surgical tool integrating electrosurgery and class-leading surgical smoke control in a single laparoscopic device, designed to deliver rapid and continuous resolution of surgical smoke.
A spin-out of the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre, Alesi Surgical benefits from unique access to experienced surgeons and trainers. This allows the company to identify procedural issues and design devices to address them effectively. Its product development is informed by robust testing and advice from surgical trainers, ensuring utility, usability, and seamless integration into surgical practice. The Ultravision system is a small, stand-alone, portable unit fully compatible with current laparoscopic equipment.
The $8.7 million in secured capital is earmarked to fuel Alesi Surgical's strategic growth initiatives. The company plans to allocate the funds towards expanding its research and development efforts, further enhancing its product pipeline, and scaling its market presence, particularly for the Ultravision2 system. This investment is expected to accelerate the company's ability to bring its innovative surgical technologies to a broader market.
This funding round underscores confidence in Alesi Surgical's needs-driven approach to surgical technology and its potential to significantly improve patient safety and surgical outcomes globally. The company is positioned to continue its trajectory of innovation and market expansion in the medical device sector.
